Viruses and Bacteria
Imbalance between CD8+CD28+ and CD8+CD28- T-cell subsets and its clinical significance in patients with systemic lupus erythematosus. These data suggest that high expression of Fas, FasL and IL-6 and low expression of CTLA-4 by the CD8+CD28+ T-cell subset promotes the activation-induced cell death of the CD8+CD28+ T-cell subset. PubMed, Lupus, 2019 Aug 9:961203319867130. (Also see B Cells and T Cells)
Aberrant T cell subsets and cytokines expression profile in systemic lupus erythematosus (SLE). T cell subsets and levels of chemokines and cytokines in patients with SLE and their relationships between disease activity and organ involvement were assessed. PubMed, Clin Rheumatol, 2018 Sep;37(9):2405-2413. (Also see B Cells and T Cells)
Increased lipid and protein oxidation and lowered anti–oxidant defenses in systemic lupus erythematosus are associated with severity of illness, autoimmunity, increased adhesion molecules. Increased nitro–oxidative stress takes part in the (auto)immune pathophysiology of SLE and modulates severity of illness and adhesion molecule expression. PubMed, Immunol Res, 11/29/2017.
Activating and inhibitory receptors on natural killer cells in patients with systemic lupus erythematosis (SLE)–regulation with interleukin-15. Natural killer (NK) cells may play an important role in the pathogenesis of SLE. PubMed, PLoS One, 2017 Oct 12;12(10):e0186223. (Also see Natural Killer Cells)
A Stress Link to Lupus. Psychological trauma is associated with an increased risk for lupus, a new study reports. New York Times, 09/20/2017.
Immune complexes containing serum B-cell activating factor (BAFF) and immunoglobulin G (IgG) correlate with disease activity in systemic lupus erythematosus (SLE). BAFF–IgG complexes strongly correlate with disease activity in SLE patients, suggesting a pathogenic role in SLE. Nephrology Dialysis Transplantation, 08/08/2017.
Endothelial Alterations in Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA): Potential Effect of Monocyte Interaction. This paper aims to review some aspects about the endothelial activation and dysfunction in the context of SLE and RA, as well as the potential role that monocytes apparently play in this process. PubMed, Mediators Inflamm, 2017;2017:9680729. (Also see Causes of Rheumatoid Arthritis)
Expression of CCR6 on B cells in systemic lupus erythematosus patients. Pre–germinal centre B cells are found in lower proportions and the expression of CCR6 is increased on B cells of SLE patients, suggesting a role for the chemokine pair in the pathogenesis of the disease. PubMed, Clin Rheumatol, 2017 Jun;36(6):1453-1456. (Also see B Cells and T Cells)
New Genetic Mutation That Halts The Development Of Lupus Discovered. The lupus-suppressing action is the result of what is known as a nonsense mutation of the Coronin-1A gene (Coro1a) required for the development of the disease. ScienceDaily.
Mechanistic insights into environmental and genetic risk factors for systemic lupus erythematosus (SLE). This information is expected to provide practical insights into these risk factors in order to benefit patients with SLE and facilitate the development of potential therapeutic strategies. PubMed, Am J Transl Res, 2019 Mar 15;11(3):1241-1254.
The interaction between environmental triggers and epigenetics in autoimmunity. Reactive oxygen species that inhibit Dnmt1 upregulation, and a diet poor in methyl donors, combine to cause lupus in animal models. PubMed, Clin Immunol, 04/09/2018.
Differential expression of the inflammasome complex genes in systemic lupus erythematosus (SLE). The data in this investigation emphasized once more the important contribution of inflammasome in SLE-associated inflammation. PubMed, Immunogenetics, 02/05/2020.
Associations between paraoxonase-1 and systemic lupus erythematosus. Meta-analyses revealed reduced paraoxonase-1 activity in patients with systemic lupus erythematosus. PubMed, Lupus, 2019 Nov;28(13):1571-1576.
Association of TNFSF4 rs1234315, rs2205960 polymorphisms and systemic lupus erythematosus (SLE) susceptibility: a meta-analysis. The present study suggested that TNFSF4 rs1234315 and rs2205960 polymorphisms were associated with SLE susceptibility. PubMed, Lupus, 2019 Jul 12:961203319862610.
Gene–function studies in systemic lupus erythematosus (SLE). The work discussed in this review has broad implications for our understanding of the pathogenesis of SLE and for the development of novel therapeutic strategies. PubMed, Curr Opin Rheumatol, 2019 Mar;31(2):185-192.
Association of interleukin 13 gene polymorphisms and plasma IL 13 level with risk of systemic lupus erythematosus (SLE). The concentration of IL-13 was significantly elevated in rs20541 CT/TT genotypes compared with CC genotype which suggests that rs20541 CT/TT genotypes may be a risk factor for SLE. PubMed, Cytokine, 10/07/2017. (Also see Interleukins)
Contraception in patients with systemic lupus erythematosus and antiphospholipid syndrome. Contraceptive choice in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) is challenging but important. Long-acting forms of contraception such as the progesterone intrauterine device (IUD) or subdermal implant are preferable for most patients. Sage Journals, Lupus.
The microbiome and systemic lupus erythematosus. This new knowledge, along with that enabling alteration in composition of the gut microbiome, via diet modification, antibiotic, and probiotics, may bring forward a new era in the future of lupus treatment. PubMed, Immunol Res, 2017 Apr;65(2):432-437.
Immune responses to an early lytic cytomegalovirus (CMV) antigen in systemic lupus erythematosus (SLE) patients: T-cell responses, cytokine secretions and antibody status. The dysfunctional immune response against Epstein-Barr virus previously established in SLE patients does not seem to apply to the same degree regarding the immune responses against CMV or human herpes virus 6. PubMed, PLoS One, 2018 Mar 2;13(3):e0193244.
We have the world's best supporters! See ISN News.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to: